Postpartum hemorrhaging (PPH) is the leading cause of maternal deaths globally. InPress Technologies, founded by Cal Poly alum Jessie Becker, wants to change that statistic with their product, the InPress device. Clinically, 80% of the instances of PPH are caused by the failure of the uterus to contract after childbirth1. The InPress device addresses this problem by enabling the natural contraction of the uterus and preventing excessive bleeding without dangerous and invasive operations.
Founded in 2011 after participating in Innovation Quest, InPress is continually connecting with the right people. After involvement with the Cal Poly Center for Innovation & Entrepreneurship’s (CIE) Incubator program, the company went on to secure a spot in the elite biomedical incubator program at the Fogarty Institute for Innovation.
Splitting their time between Mountain View and San Luis Obispo, the InPress team just wrapped up their First in Woman clinical trial, has built a strong patent portfolio, and is currently raising their Series A round of financing.
“We’re feeling pretty well equipped to move forward,” said Becker.
The team is set to meet with the FDA for the first time and will soon apply for a CE Mark to be able to sell their device in the European market.
Despite all the approvals and applications required to move their product to market, InPress is centered around changing women’s lives. Becker and her team hope to see their device all over the world, especially in developing nations with limited access to modern healthcare. They believe this device will change the world, and after hearing them talk about InPress, it’s hard not to agree.
If you would like to learn more about InPress, or if you’re interested in investing in the company, go tohttp://www.inpresstechnologies.com
1 via InPress Technologies